Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity

Clinical Pharmacology and Therapeutics

Volumn 61, Issue 6, 1997, Pages 628-640

  Lee, Toong Chow ^b   Charles, Bruce ^a   Steer, Peter ^b   Flenady, Vicki ^b   Shearman, Andrew ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CAFFEINE CITRATE;

AGE; APNEA; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEWBORN; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

APNEA; CAFFEINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFUSIONS, INTRAVENOUS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SINGLE-BLIND METHOD;

EID: 0030915015     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90097-7     Document Type: Article

References (32)

1. Alden ER, Mandelkorn T, Woodrum DE, Wennberg RP, Parks CR, Hudson WA. Morbidity and mortality of infants weighing less than 1000 grams in an intensive care nursery. Pediatrics 1972;50:40-8.
2. Henderson-Smart DJ. The effect of gestational age on the incidence and duration of recurrent apnoea in newborn babies. Aust Paediatr J 1981;17:273-6.
3. Poets CF, Samuels MP, Southall DP. Epidemiology and pathophysiology of apnoea of prematurity. Biol Neonate 1994;65:211-9.
4. Tudehope DI, Rogers YM, Burns YR, Mohay H, O'Callaghan MJ. Apnoea in very low birth weight infants: outcome at 2 years. Aust Paediatr J 1986;22: 131-4.
5. Aranda JV, Turmen T. Methylxanthines in apnea of prematurity. Clin Perinatal 1979;6:87-108.
6. Sims ME, Rangasamy R, Lee S, Chung H, Cohen J, Walther FJ. Comparative evaluation of caffeine and theophylline for weaning premature infants from the ventilator. Am J Perinatol 1989;6:72-5.
7. Aranda JV, Cook CE, Gorman W, Collinge JM, Loughnan PM, Outerbridge EW, et al. Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. J Pediatr 1979;94:664-8.
8. Scanlon JEM, Chin KC, Morgan MEI, Durbin GM, Hale KA, Brown SS. Caffeine or theophylline for neonatal apnoea? Arch Dis Child 1992;67:425-8.
9. Aranda JV, Gorman W, Bergsteinsson H, Gunn T. Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. J Pediatr 1977;90:467-72.
10. Davis JM, Spitzer AR, Stefano JL, Bhutani V, Fox WW. Use of caffeine in infants unresponsive to theophylline in apnoea of prematurity. Pediatr Pulmonol 1987;3:90-3.
11. Collart L, Blaschke TF, Boucher F, Prober CG. Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates. Dev Pharmacol Ther 1992;18:71-80.
12. Thomson AH, Kerr S, Wright S. Population pharmacokinetics of caffeine in neonates and young infants. Ther Drug Monit 1996;18:245-53.
13. Boeckmann A, Sheiner L, Beal S. NONMEM users' guide. San Francisco: NONMEM Project Group, 1992.
14. Grasela TH, Sheiner LB. Pharmacostatistical modeling for observational data. J Pharmacokinet Biopharm 1991;19:25S-36S.
15. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-12.
16. Lee TC, Charles BG, Steer PA, Flenady VJ, Grant TC. Theophylline population pharmacokinetics from routine monitoring data in very premature infants with apnoea. Br J Clin Pharmacol 1996;41:191-200.
17. Bucher HU, Duc G. Does caffeine prevent hypoxaemic episodes in premature infants? Eur J Pediatr 1988;147:288-91.
18. Pearlman SA, Duran C, Wood MA, Maisels MJ, Berlin CM. Caffeine pharmacokinetics in preterm infants older than 2 weeks. Dev Pharmacol Ther 1989;12:65-9.
19. Gorodischer R, Karplus M. Pharmacokinetic aspects of caffeine in premature infants with apnoea. Eur J Clin Pharmacol 1982;22:47-52.
20. Aranda JV, Collinge JM, Zinman R, Watters G. Maturation of caffeine elimination in infancy. Arch Dis Child 1979;54:946-9.
21. Morselli PL, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants: agerelated differences and therapeutic implications. Clin Pharmacokinet 1980;5:485-527.
22. Pons G, Carrier O, Richard MO, Rey E, d'Athis P, Moran C, et al. Developmental changes of caffeine elimination in infancy. Dev Pharmacol Ther 1988;11:258-64.
23. Stavric B. Methylxanthines-toxicity to humans; II: caffeine. Food Chem Toxicol 1988;26:645-62.
24. Bory C, Baltassat P, Porthault M, Bethenod M, Frederich A. Metabolism of theophylline to caffeine in premature newborn infants. J Pediatr 1979;94:988-93.
25. Bonati M, Latini R, Galletti F, Young JF, Tognoni G, Garattini S. Caffeine disposition after oral doses. Clin Pharmacol Ther 1982;32:98-106.
26. Kennedy JS, Leduc BW, Scavone JM, Harmatz JS, Shader RI, Greenblatt DJ. Pharmacokinetics of intravenous caffeine: comparison of high-performance liquid Chromatographic and gas Chromatographic methods. J Chromatogr 1987;422:274-80.
27. Cheng WSC, Murphy TL, Smith MT, Cooksley WGE, Halliday JW, Powell LW. Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function. Clin Pharmacol Ther 1990; 47:516-24.
28. Denaro CP, Brown CR, Wilson M, Jacob P, Benowitz NL. Dose-dependency of caffeine metabolism with repeated dosing. Clin Pharmacol Ther 1990;48:277-85.
29. Aldridge A, Aranda JV, Neims AH. Caffeine metabolism in the newborn. Clin Pharmacol Ther 1979;25:447-53.
30. Heimler R, Nemeth P, Yassin M, Jendrzejczak B, Doumas B. Total body water and extracellular water of premature infants during the first week of life [abstract]. Clin Res 1990;38:825a.
31. Warszawsiki D, Gorodischer R. Tissue distribution of caffeine in premature infants and in newborn and adult dogs. Pediatr Pharmacol 1981;1:341-6.
32. Blanchard J. Protein binding of caffeine in young and elderly males. J Pharm Sci 1982;71:1415-8.